Multiple Myeloma in the Black Community

Multiple myeloma is one of those cancers that rarely introduces itself politely. It often starts with vague symptomsfatigue, back pain, repeated infections, or “I thought I was just getting older” signsand by the time someone gets the right tests, the disease may already be affecting bones, kidneys, or blood counts.

That challenge matters for everyone, but it matters especially in the Black community. In the United States, Black adults are diagnosed with multiple myeloma at much higher rates than White adults, and many are diagnosed younger. At the same time, Black patients often face structural barriers such as delayed diagnosis, fewer specialty referrals, lower access to novel therapies, and lower participation in clinical trials. The frustrating part? When access to high-quality care is equitable, outcomes can be much more comparable.

This article breaks down the big picture in plain English: what multiple myeloma is, why it affects Black communities differently, what symptoms to watch for, how diagnosis and treatment work, and how patients and families can advocate for better care. This is educational content, not a personal medical diagnosisbut it can help you ask sharper questions and get to the right care faster.

Why This Topic Matters

Multiple myeloma is still considered a relatively uncommon cancer overall, but it is one of the most important blood cancers to understand because it can quietly cause serious damage. In recent U.S. estimates, tens of thousands of people are diagnosed each year, and most are diagnosed at age 65 or older. The average age at diagnosis is around 69.

Here’s the key equity issue: multiple myeloma is more than twice as common in Black people as in White people. National cancer data and leading cancer organizations consistently show this pattern. In practical terms, that means Black families are more likely to encounter myelomaand more likely to need early awareness, specialist care, and long-term support.

Another reason this topic matters: Black patients are often diagnosed about five years younger on average than White patients. That affects everything from employment and caregiving responsibilities to insurance stability and treatment logistics. A diagnosis at 62 can look very different from a diagnosis at 72 if you’re still working, supporting parents, or helping adult children.

What Multiple Myeloma Is

Multiple myeloma is a cancer of plasma cells, a type of white blood cell made in the bone marrow. Normally, plasma cells help fight infection by making antibodies. In myeloma, abnormal plasma cells grow out of control, crowd healthy blood-forming cells, and produce unhealthy proteins (often called M proteins) that can damage organs.

This can lead to the classic myeloma problems many specialists watch for:

• Bone damage and bone pain (especially in the back, hips, ribs, or skull)
• Low blood counts (like anemia, causing fatigue and weakness)
• Kidney problems
• High calcium levels (which can cause confusion, constipation, thirst, or worse)
• Frequent infections

One important thing to know: some people have no obvious symptoms at first. That’s one reason myeloma can be missed or diagnosed late. A person may be treated several times for “normal back pain” or “just anemia” before someone connects the dots.

Why the Burden Is Higher in the Black Community

1) Higher underlying risk and more MGUS

Most multiple myeloma begins as a precursor condition called MGUS (monoclonal gammopathy of undetermined significance). MGUS itself is not cancer, and many people with MGUS never develop myeloma. But it is a major risk marker, and researchers have found that MGUS is more common in Black populations.

In fact, major myeloma organizations and NIH-linked research report that MGUS is roughly two times (and in some sources, two to three times) more common in Black people than in White populations. That higher baseline prevalence helps explain why multiple myeloma is diagnosed more often in the Black community.

Researchers are still studying the “why” behind this pattern. Biology may play a role, but biology is only part of the story. The bigger picture includes family history patterns, obesity-related risk, and the way social and healthcare systems shape who gets screened, who gets diagnosed early, and who gets access to advanced treatment.

2) Delayed diagnosis is common

Myeloma symptoms can be sneaky. Fatigue can look like stress. Bone pain can look like arthritis. Kidney issues can look like dehydration or diabetes complications. In Black patients, delayed diagnosis may be more common due to a combination of symptom overlap, lower awareness in primary care settings, and slower referral to hematology/oncology specialists.

Delays matter because untreated myeloma can continue causing bone damage, kidney injury, and anemia. A delay of months can affect stage, treatment intensity, and recovery.

3) Access gaps, not just biology, drive disparities

This is a crucial point: disparities in myeloma outcomes are not just about genetics or risk. They are also about access. Black patients may have less access to full diagnostic testing, novel therapies, transplant centers, CAR T-cell therapy programs, and clinical trials. Financial toxicity, transportation, work schedules, insurance barriers, and mistrust of the healthcare system all add friction.

The good news (and it is genuinely good news) is that when Black patients receive equitable access to modern myeloma care, outcomes can improve substantially and may be comparable across groups. That means disparities are not destiny.

Symptoms That Should Not Be Ignored

If you are in a higher-risk groupor you’re caring for someone who isknowing the warning signs can make a real difference. Multiple myeloma symptoms may include:

• Persistent bone pain, especially back pain
• Unusual fatigue or weakness
• Frequent infections (such as pneumonia or recurrent sinus infections)
• Unexplained weight loss
• Numbness or tingling
• Shortness of breath (often from anemia)
• Kidney issues or abnormal lab results
• High calcium symptoms (thirst, constipation, confusion)

These symptoms can overlap with other conditions, which is exactly why self-advocacy matters. If symptoms persist, it is reasonable to ask whether a workup for a plasma cell disorder should be consideredespecially if there is a family history of blood cancers or a prior history of MGUS.

How Multiple Myeloma Is Diagnosed

Diagnosing myeloma is not a one-test situation. Doctors usually combine several types of tests to confirm the diagnosis and understand how advanced it is.

Common tests include:

• Blood tests (to check blood counts, calcium, kidney function, and abnormal proteins)
• Urine tests (to look for protein related to myeloma)
• Bone marrow biopsy (to identify abnormal plasma cells)
• Imaging such as X-rays, CT, MRI, or PET scans (to assess bone damage and lesions)
• Genetic/cytogenetic testing (to identify high-risk features and guide treatment planning)

Staging is also important. Many clinicians use the Revised International Staging System (R-ISS) or newer staging updates to estimate disease risk and help guide treatment. In plain English: staging helps doctors understand how aggressive the disease may be and which therapies are most likely to help.

Treatment Options and What Equitable Care Looks Like

Myeloma treatment has improved dramatically in the last two decades. While there is still no guaranteed cure for most patients, many people now live longer and better with modern treatment combinations. Some patients do not need treatment immediately (for example, smoldering myeloma without symptoms), while others need prompt therapy.

Typical treatment building blocks

• Targeted therapy (including proteasome inhibitors)
• Immunotherapy (including immunomodulatory drugs and monoclonal antibodies)
• Corticosteroids (such as dexamethasone)
• Chemotherapy (in certain regimens and settings)
• Stem cell transplant (for eligible patients)
• CAR T-cell therapy and other advanced therapies (often in specialized centers)
• Supportive care for bone health, kidney protection, infection prevention, and anemia

Many treatment plans use a combination approach. A patient may start with a multi-drug regimen, then move to stem cell transplant (if eligible), followed by maintenance therapy. Others may receive non-transplant regimens depending on age, overall health, disease risk, and personal goals.

What “equitable care” should look like

For Black patients and families, equitable myeloma care means more than prescribing medicine. It means:

• Fast referral to a hematologist/oncologist (or myeloma specialist)
• Complete diagnostic testing, including genetics and imaging
• A real discussion about transplant eligibilitynot assumptions based on age, race, or zip code
• Clear information about clinical trials
• Help with transportation, costs, insurance, and scheduling
• Communication that is respectful, culturally responsive, and easy to understand

This is where many care systems still fall short. But awareness is improving, and organizations focused on myeloma are building more community-specific education and support programs to close these gaps.

Clinical Trials and Representation

Clinical trials are not “last resort” care. In myeloma, they are often how patients gain access to promising new therapies and how doctors improve treatment for everyone. But Black patients remain underrepresented in oncology trials, including myeloma trials.

Underrepresentation is a science problem and an equity problem. If trial participants do not reflect the people most affected by a disease, researchers may miss important differences in treatment response, side effects, and long-term outcomes.

Barriers to trial enrollment can include transportation, childcare, work schedules, insurance concerns, lack of trial discussion during appointments, and mistrust rooted in historical and present-day inequities. The solution is not to blame patients. The solution is to design better systems: community-based enrollment pathways, patient navigators, clearer information, and stronger partnerships between academic centers and local clinicians.

How Patients and Families Can Advocate for Better Care

Nobody wants to become a part-time project manager for a cancer diagnosisbut in the real world, a little organization can help a lot. Here are practical steps that make a difference:

1) Ask for a myeloma specialist opinion

Even if you love your local oncologist, a second opinion from a myeloma-focused specialist can help confirm the diagnosis, risk level, and treatment plan. Myeloma care changes fast, and specialists often know the newest combinations and trials.

2) Request complete testing

Ask what tests were done and what is still needed. It is okay to ask directly: “Do we have bone marrow results, genetic risk testing, and imaging?” Clear records can prevent delays and confusion.

3) Bring a support person

Appointments can feel like a firehose of information. A family member or friend can take notes, ask follow-up questions, and help remember what was said. Teamwork beats panic every time.

4) Ask about financial and transportation help early

Don’t wait until bills pile up. Many cancer centers and advocacy groups offer financial counseling, transportation support, medication assistance, or social work resources. These supports can improve treatment adherence and reduce stress.

5) Bring up clinical trials early, not only later

A simple question works: “Are there any clinical trials that fit my situation now or soon?” Asking early creates options.

Experiences in the Black Community: What Patients and Families Often Describe

The experiences below are a composite of common themes reported by patients, caregivers, clinicians, and advocacy groups. They are not one person’s story, but they reflect what many families describe when facing multiple myeloma in the Black community.

The “it was probably nothing” phase

A lot of journeys begin with a symptom that doesn’t scream “blood cancer.” It might be back pain after lifting groceries, constant fatigue blamed on work, or lab results showing anemia that gets chalked up to stress. Someone goes to urgent care, then a primary doctor, then maybe another visit when things still don’t improve. By the third or fourth appointment, frustration builds. Patients often say they knew something was wrong before the system caught up.

For Black patients, this stage can carry an extra emotional weight: “Am I being heard?” Some people describe feeling dismissed, rushed, or told to “watch and wait” without a clear explanation. Even when clinicians mean well, a lack of communication can feel like a lack of concern.

The diagnosis shock

Then comes the diagnosis, and life changes in one conversation. Families often describe a blur of unfamiliar words: plasma cells, M protein, bone marrow biopsy, transplant eligibility, induction therapy. It’s not uncommon for the patient to leave the clinic remembering only about 20% of what was said and one unforgettable sentence: “You have cancer.”

Caregivers step in fast. A daughter starts a notebook. A cousin makes a spreadsheet. A church friend organizes rides. Someone creates a group chat that pings nonstop with “How did the appointment go?” and “Did he eat today?” It’s not fancy, but it’s a care system.

The barrier marathon

Treatment can be lifesaving, but logistics can feel like a second diagnosis. Patients may have to travel to a larger cancer center for specialist care or advanced therapies. Time off work becomes a problem. Transportation becomes a problem. Parking becomes a problem. Insurance approvals become a full-contact sport.

Families often describe having to fight on two fronts: fighting the disease and fighting the paperwork. This is one reason patient navigation and social work support matter so much. When the system is easier to navigate, patients are more likely to stay on track with treatment.

Trust, communication, and community

Trust is a major theme. Patients consistently say they do better when clinicians take time to explain the plan, listen without talking over them, and acknowledge real-world concerns like cost, transportation, and family obligations. Respectful communication is not a “nice extra.” It is part of quality care.

Community support is also huge. In many Black families, health decisions are not made alone. Faith leaders, siblings, adult children, and close friends may all be involved. When healthcare teams welcome that support system instead of treating it like an inconvenience, patients often feel stronger, more informed, and less isolated.

Living with myeloma, not just treating it

Another common experience: people learn that myeloma care is a long game. There are treatment cycles, side effects, follow-up labs, and moments of uncertainty. But there are also winsnumbers improving, pain decreasing, energy returning, grandkids visited, birthdays celebrated, a normal Tuesday that suddenly feels like a trophy.

Many patients describe becoming advocates over time. They start asking better questions. They push for second opinions. They encourage relatives to get checked when symptoms are ignored. They remind others that “twice as common” does not mean “hopeless.” It means we need awareness, faster diagnosis, and better accessespecially in communities carrying a heavier burden.

Final Thoughts

Multiple myeloma in the Black community is a story of both risk and resilience. The disease is more common, often diagnosed younger, and still shaped by inequities in access to care. But the modern treatment era is changing what is possible, and many of the worst outcomes are not inevitable.

The most important takeaway is simple: early recognition, specialist care, and equitable access matter. If patients are heard, tested thoroughly, and connected to the right therapies and support systems, they have a much better shot at living longer and living well.

If you or someone you love has symptoms that don’t make senseor a diagnosis that came with more questions than answersask for clarity, ask for records, and ask for a specialist. In myeloma, good questions are not being difficult. They are part of good care.